1. Home
  2. ERAS vs CMCL Comparison

ERAS vs CMCL Comparison

Compare ERAS & CMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • CMCL
  • Stock Information
  • Founded
  • ERAS 2018
  • CMCL 1992
  • Country
  • ERAS United States
  • CMCL Jersey
  • Employees
  • ERAS N/A
  • CMCL N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • CMCL Precious Metals
  • Sector
  • ERAS Health Care
  • CMCL Basic Materials
  • Exchange
  • ERAS Nasdaq
  • CMCL Nasdaq
  • Market Cap
  • ERAS 484.4M
  • CMCL 445.3M
  • IPO Year
  • ERAS 2021
  • CMCL N/A
  • Fundamental
  • Price
  • ERAS $1.58
  • CMCL $24.53
  • Analyst Decision
  • ERAS Strong Buy
  • CMCL Strong Buy
  • Analyst Count
  • ERAS 6
  • CMCL 1
  • Target Price
  • ERAS $4.50
  • CMCL $28.00
  • AVG Volume (30 Days)
  • ERAS 714.7K
  • CMCL 181.6K
  • Earning Date
  • ERAS 08-12-2025
  • CMCL 08-11-2025
  • Dividend Yield
  • ERAS N/A
  • CMCL 2.27%
  • EPS Growth
  • ERAS N/A
  • CMCL 432.25
  • EPS
  • ERAS N/A
  • CMCL 1.92
  • Revenue
  • ERAS N/A
  • CMCL $204,738,000.00
  • Revenue This Year
  • ERAS N/A
  • CMCL $41.61
  • Revenue Next Year
  • ERAS N/A
  • CMCL N/A
  • P/E Ratio
  • ERAS N/A
  • CMCL $13.17
  • Revenue Growth
  • ERAS N/A
  • CMCL 28.06
  • 52 Week Low
  • ERAS $1.01
  • CMCL $8.81
  • 52 Week High
  • ERAS $3.31
  • CMCL $26.06
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 53.64
  • CMCL 56.46
  • Support Level
  • ERAS $1.44
  • CMCL $24.15
  • Resistance Level
  • ERAS $1.64
  • CMCL $25.68
  • Average True Range (ATR)
  • ERAS 0.10
  • CMCL 1.64
  • MACD
  • ERAS 0.01
  • CMCL 0.11
  • Stochastic Oscillator
  • ERAS 61.54
  • CMCL 73.94

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About CMCL Caledonia Mining Corporation Plc

Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.

Share on Social Networks: